Equities research analysts predict that Dynavax Technologies Co. (NASDAQ:DVAX) will report earnings per share of ($0.58) for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Dynavax Technologies’ earnings, with the highest EPS estimate coming in at ($0.56) and the lowest estimate coming in at ($0.60). Dynavax Technologies posted earnings of ($0.38) per share during the same quarter last year, which would indicate a negative year over year growth rate of 52.6%. The business is scheduled to announce its next earnings report on Friday, November 2nd.
On average, analysts expect that Dynavax Technologies will report full-year earnings of ($2.39) per share for the current financial year, with EPS estimates ranging from ($2.42) to ($2.33). For the next year, analysts forecast that the firm will post earnings of ($1.46) per share, with EPS estimates ranging from ($1.70) to ($1.23). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Dynavax Technologies.
Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Monday, August 6th. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.01). Dynavax Technologies had a negative net margin of 8,570.06% and a negative return on equity of 72.31%. The company had revenue of $1.25 million for the quarter, compared to the consensus estimate of $1.88 million. During the same period in the prior year, the firm posted ($0.41) EPS. The business’s revenue was up 1094.3% on a year-over-year basis.
A number of large investors have recently modified their holdings of the stock. Northern Trust Corp grew its holdings in Dynavax Technologies by 9.8% in the second quarter. Northern Trust Corp now owns 750,442 shares of the biopharmaceutical company’s stock worth $11,445,000 after purchasing an additional 66,677 shares during the last quarter. Bain Capital Public Equity Management LLC purchased a new position in Dynavax Technologies in the second quarter worth $4,198,000. Millennium Management LLC grew its holdings in Dynavax Technologies by 184.6% in the second quarter. Millennium Management LLC now owns 129,902 shares of the biopharmaceutical company’s stock worth $1,981,000 after purchasing an additional 84,254 shares during the last quarter. PointState Capital LP purchased a new position in Dynavax Technologies in the second quarter worth $28,800,000. Finally, First Light Asset Management LLC grew its holdings in Dynavax Technologies by 21.0% in the second quarter. First Light Asset Management LLC now owns 548,777 shares of the biopharmaceutical company’s stock worth $8,369,000 after purchasing an additional 95,143 shares during the last quarter. 82.02% of the stock is owned by institutional investors.
Shares of Dynavax Technologies stock traded down $0.30 on Thursday, hitting $12.10. 585,800 shares of the company traded hands, compared to its average volume of 1,358,197. The company has a debt-to-equity ratio of 0.76, a quick ratio of 8.67 and a current ratio of 8.87. Dynavax Technologies has a 52 week low of $11.35 and a 52 week high of $24.45. The company has a market capitalization of $776.43 million, a PE ratio of -7.08 and a beta of 0.24.
About Dynavax Technologies
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.
Read More: Why is the conference call important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.